Abstract
In Parkinson's disease (PD), long-term use of levodopa-induced dyskinesia (LID) significantly affects the therapeutic efficacy of levodopa and quality of life of patients. Current existing therapies are not ideal, which is related to that mechanism of LID has not been fully clarified. Recently, more and more studies have confirmed that the glutamatergic system is closely related to the dopaminergic system, and the role of glutamate receptors in LID is increasingly prominent, especially, metabolic glutamate receptor (mGluR)4, mGluR 5 and partial ionotropic glutamate receptors are current research hotspots in the mechanism and clinical observation of drugs of LID. Therefore, this review summarizes the changes and roles of various glutamate receptors in LID and related clinical studies, hoping to provide new ideas for the diagnosis and treatment of LID in PD patients. Key words: Glutamate receptor; Levodopa; Dyskinesia; Parkinson's disease
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
